To exam the enhanced cell surface binding of nanobodies after affinity maturation and Fc domain fusion, we tested the cell saturation of VHH-Fc compared to trastuzumab via flow cytometry in a HER2-expressing tumor cell NCI-N87 (Figure 2E). This evidence concerns the gene ERBB2 and neoplasm.